Navigation Links
PET imaging used to more accurately manage treatment, predict survival for patients with gliomas
Date:12/3/2012

Reston, Va. (December 3, 2012) In the management of gliomasor tumors that originate in the brainprecise assessment of tumor grade and the proliferative activity of cells plays a major role in determining the most appropriate treatment and predicting overall survival. Research published in the December issue of The Journal of Nuclear Medicine (JNM) highlights the potential of imaging with 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) positron emission tomography (PET) to noninvasively and accurately provide tumor-specific details to guide management of patients with gliomas.

Gliomas are uncommon neoplasms, and most are diffuse tumors that grow quickly. Patients with glioblastoma, the most malignant and most frequent type of glioma, typically die within two years. Ensuring the most appropriate treatment in a timely manner is of utmost importance for these patients.

Two studies in the December issue of JNM explore the utility of F-18-FLT PET for providing prognostic information for patients with gliomas. "The accumulation of F-18-FLT is dependent on the presence of thymidine kinase-1, which is closely associated with cellular proliferation. In several clinical studies, F-18-FLT has been validated for evaluation of tumor grade and cellular proliferation in gliomas," noted Yuka Yamamoto, MD, lead author of the study, "Correlation of 18F-FLT Uptake with Tumor Grade and Ki-67 Immunohistochemistry in Patients with Newly Diagnosed and Recurrent Gliomas."

In the study led by Yamamoto, researchers retrospectively evaluated F-18-FLT uptake in patients with newly diagnosed (36 patients) and recurrent (20 patients) gliomas. Patients underwent F-18-FLT PET scans; tissue specimens were then taken to obtain a pathological diagnosis. The F-18-FLT images were analyzed by two nuclear medicine physicians, who identified tumor lesions as areas of focally increased uptake exceeding that of normal brain background, and who determined the tumor-to-normal (T/N) ratio. Results the 18-F-FLT PET scan were compared with tumor grade and proliferative activity estimated from the tissue specimens.

Researchers found that there was significant difference in the T/N ratio among different grades of newly diagnosed and recurrent gliomas. F-18-FLT uptake correlated more strongly with the proliferative activity in newly diagnosed gliomas than in recurrent gliomas and provided a more comprehensive view to determine tumor grade as compared to a single tissue specimen.

The correlation between proliferative volume and prediction of overall survival for high-grade glioma patients was also examined in the article "3'-Deoxy-3'-18F-Fluorothymidine PET-Derived Proliferative Volume Predicts Overall Survival in High-Grade Glioma Patients." In the study, 26 consecutive patients underwent preoperative 18-F-FLT PET/computed tomography (CT) scans. The maximum standardized uptake value (SUVmax) was calculated and three different PET segmentation methods were used to estimate the proliferative volume. The prognostic value of the SUVmax and the different methods to approximate proliferative volume for overall survival were then assessed.

The mean overall survival for the patients in the study was 397 days; 19 patients died during this time. Based on this follow-up information, researchers determined that the signal-to-background ration (SBR) for an adaptive threshold delineation (PVSBR) method showed a significantly better association with overall survival then the SUVmax or the other two PET segmentation methods.

"The predictive value of the proliferative volume for the overall survival of patients seems to be independent of the postoperative treatment," explained Albert J.S. Idema, MD, lead author of the study. "The importance for patients is the possible utilization of 18-F-FLT PET to select the most appropriate treatment options. The very limited burden that the procedure causes to the patient is a further asset."

The development of new molecular imaging agents, such as F-18-FLT, which is currently used only for research purposes, has enabled clinical researchers to utilize the agents to assess the characteristics of tumors and their therapeutic response. "We hope that these findings will be helpful for identifying the role of F-18-FLT in assessing the response to antiproliferative treatment in patients with gliomas," said Yamamoto.


'/>"/>
Contact: Susan Martonik
smartonik@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Amyloid imaging helps in evaluating possible Alzheimer disease
2. Breast cancer risk estimates increased with repeated prior ct and nuclear imaging
3. University Hospitals & Philips Healthcare to showcase imaging technology at Cleveland Medical Mart
4. Imaging shows some brains compensate after traumatic injury
5. Neuroimaging study: Negative messages less effective on those who are substance dependent
6. How do cells tell time? Scientists develop single-cell imaging to watch the cell clock
7. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
8. Imaging speeds early diagnosis of heart disease, the top killer in the Western world
9. Imaging facility develops successful radiation dose reduction program
10. Is declining medical imaging use driving up hospital stays and medical costs?
11. FDA OKs First Ultrasound Imaging System for Dense Breasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... How big is ... facilities, and who are the most active developers? , In the first ... Real Estate Insights (HREI) found that outpatient medical real estate development projects totaling ...
(Date:3/29/2017)... ... 29, 2017 , ... The assembly of synthetic DNA has ... repetitive steps and often scientists require many different versions of DNA. Therefore, this ... in a lower error rate and cost saving for reagents and consumables. , ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... The Wharton ... WG’81, and Julie Taffet Moelis, W’81, have made a $10 million gift to establish ... admission opportunity that will provide a pathway to a Wharton MBA for highly-qualified Penn ...
(Date:3/28/2017)... , ... March 28, 2017 , ... For many women, getting birth control isn’t as ... , meaning they either don’t have access to a health care facility or a pharmacy ... remote regions of the United States or for many who are faced with health or ...
(Date:3/28/2017)... ... 29, 2017 , ... The Thyroid Secret is a specialized ... The program was recently launched on March 1, and Dr. Wentz discussed varied ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid specialist. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)... , March 29, 2017  Maxor National Pharmacy ... announced that it has named Leah Bailey ... all divisions of the company. With more ... the previous 8 years focused on health care, Bailey ... her tenure at Prime, Bailey advised the PBM, Specialty, ...
(Date:3/29/2017)... Varian Medical Systems (NYSE: VAR ) ... quarter of fiscal year 2017 following the close of regular ... be followed by a teleconference available to all interested parties ... to the conference call webcast will be available on the ... call and replay: ...
Breaking Medicine Technology: